ROCKVILLE, Md., Dec. 6, 2022
/PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc.
(Nasdaq: SHPH), a discovery and development stage specialty
pharmaceutical company focused on improving the outcomes of cancer
patients treated with radiation therapy (RT), today announced the
publication of a manuscript discussing prostate cancer cell lines
derived from African American men for precision medicine. The
manuscript, titled "Novel paired normal prostate and prostate
cancer model cell systems derived from African American patients,"
by Dr. Mira Jung was published in
Cancer Research Communications, a journal affiliated with the
American Association for Cancer Research (AACR), the premier
international cancer research society.
Unique cell cultures were developed by a collaborative
effort of Shuttle Pharma and Georgetown
University scientists and clinicians in a "Moonshot" project
funded by the NIH SBIR program to address prostate cancer health
disparities in African American men. Prostate cancer is the most
frequently diagnosed solid malignancy in men. African American (AA)
men are at greater risk for developing prostate cancer, and
experience higher mortality rates, as compared to Caucasian
American (CA) men. However, mechanistic studies to understand this
health disparity have been limited by the lack of relevant in vitro
and in vivo models. There is an urgent need for preclinical
cellular models to investigate molecular mechanisms underlying
prostate cancer in AA men. By collecting clinical specimens from
radical prostatectomies of AA patients, ten paired tumor-derived
and normal epithelial cell cultures were established from the same
donors and cultivated to extend the growth under "conditional
reprogramming (CR)."
"These cells can be used to study basic biological mechanisms of
cancer and they can be used for screening drugs or to determine
effectiveness of cancer therapeutics," commented Scott Grindrod, the principal investigator and
Laboratory Chief at Shuttle Pharmaceuticals.
Consistent with NIH SBIR funding goals, private companies are
encouraged to collaborate with academic institutions to develop and
commercialize novel technologies. This research project advances
research into prostate cancer health disparities for African
American men.
A copy of the publication is available at:
https://shuttlepharma.com/wp-content/uploads/2022/12/crc-22-0203.pdf.
Mira Jung, PhD is a Co-Founder
& Scientific Director of Shuttle Pharmaceuticals.
Cancer Research Communications is an open access peer-reviewed
journal that encompasses the full spectrum of research on cancer.
Launched in October 2021, the journal
aims to accelerate the pace of discovery and stimulate innovation
in cancer science and medicine by providing a venue for rapid open
publication of hypotheses, methods, results, data resources, and
new knowledge in all the varied disciplines of this quickly
evolving field. Basic, translational, clinical, and
population-level cancer research advances all fall within the scope
of Cancer Research Communications. Articles report novel findings,
provide support to previously published results, or present
thought-provoking null results.
About Shuttle Pharmaceuticals
Founded in 2012 by faculty members of the Georgetown
University Medical Center, Shuttle Pharmaceuticals is a
discovery and development stage specialty pharmaceutical company
focused on improving the outcomes for cancer patients treated with
radiation therapy (RT). Our mission is to improve the lives of
cancer patients by developing therapies that are designed to
maximize the effectiveness of RT while limiting the side effects of
radiation in cancer treatment. Although RT is a proven modality for
treating cancers, by developing radiation sensitizers, we aim to
increase cancer cure rates, prolong patient survival and improve
quality of life when used as a primary treatment or in combination
with surgery, chemotherapy and immunotherapy. For more information,
please visit our website at www.shuttlepharma.com.
Safe Harbor Statement
Statements in this press release about future expectations,
plans and prospects, as well as any other statements regarding
matters that are not historical facts, may constitute
"forward-looking statements." These statements include, but are not
limited to, statements concerning the development of our company.
The words "anticipate," "believe," "continue," "could," "estimate,"
"expect," "intend," "may," "plan," "potential," "predict,"
"project," "should," "target," "will," "would" and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including factors discussed in the "Risk
Factors" section of Shuttle Pharma's IPO prospectus filed with the
SEC on August 31, 2022, and any risk
factors set forth in the Company's Quarterly Report on Form 10-Q
filed with the SEC on November 14,
2022, or any other SEC filings. Any forward-looking
statements contained in this press release speak only as of the
date hereof and, except as required by federal securities laws,
Shuttle Pharmaceuticals specifically disclaims any obligation to
update any forward-looking statement, whether as a result of new
information, future events or otherwise.
Shuttle Pharmaceuticals
Anatoly Dritschilo, M.D., CEO
240-403-4212
info@shuttlepharma.com
Investor Contacts
Lytham Partners, LLC
Robert Blum
602-889-9700
shph@lythampartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/shuttle-pharmaceuticals-manuscript-published-in-cancer-research-communications-301695219.html
SOURCE Shuttle Pharmaceuticals Holdings, Inc.